Open-label, Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205

Inclusion Criteria:

- Patients must have been enrolled in OSI-774-205, been randomized to oral etoposide
and either progressed while on study or discontinued due to unacceptable toxicity
related to etoposide

- Performance status: Lansky ≥ 50% for patients ≤ 10 years of age or younger or
Karnofsky ≥ 50% for patients greater than 10 years of age

- Patients must have recovered from any acute toxicity to any prior anti-cancer
treatment

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, serum glutamic pyruvic
transaminase (SGPT) ALT ≤ 3 x ULN

- Serum creatinine based on age OR Creatinine Clearance/Glomerular Filtration Rate
(GFR) ≥ 70 mL/min/m2

- Patients must be neurologically stable for at least 7 days before registration

- Patients, both males and females, with reproductive potential must agree to practice
effective contraceptive measures for the duration of study drug therapy and for at
least 90 days after completion of study drug therapy

- Patients must be able to take erlotinib orally

Exclusion Criteria:

- Taking strong/moderate CYP3A4 or CYP1A2 inhibitors/inducers ≤ 14 days before
registration

- Have received any other chemotherapy or immunotherapy to treat ependymoma after
discontinuation from OSI-774-205

- Taking proton pump inhibitors ≤ 14 days before registration

- Participating in another investigational drug trial while on study

- Pregnant or breast-feeding